Crosstalk Between the Gut and Brain: Importance of the Fecal Microbiota in Patient With Brain TumorsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated whether the gut microbiota differs in patients with brain tumors compared to healthy people. The researchers characterized the fecal microbial community using 16S rRNA gene amplicon sequencing. They then examined correlations between microbiota composition and clinical features of the tumors, and explored whether specific microbial markers could help diagnose brain tumors.
Who was studied?
The study recruited 158 participants in total. This included 101 patients with brain tumors, made up of 65 benign and 36 malignant cases, along with 57 age- and sex-matched healthy controls.
What were the most important findings?
Patients with brain tumors had markedly lower gut microbial ecosystem richness and evenness than healthy controls. The overall structure of the gut microbiota community was also profoundly altered in the brain tumor group. This shift included increased abundance of pathogenic bacteria such as Fusobacteriota and Proteobacteria, alongside a reduction in other taxa.
What are the greatest implications of this study?
These findings support a gut-brain crosstalk in which gut dysbiosis is associated with the presence of brain tumors, extending prior work on microbiota alterations in other CNS diseases to this tumor context. The distinct shifts toward pathogenic taxa such as Fusobacteriota and Proteobacteria suggest the gut microbiota could potentially serve as a diagnostic marker for brain tumors. Further work would be needed to determine whether these microbial changes are a cause, consequence, or bystander effect of tumor presence.